OncoMatch/Clinical Trials/NCT06713837
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Is NCT06713837 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including High intensity therapies and Low intensity therapies for acute myeloid leukemia.
Treatment: High intensity therapies · Low intensity therapies — This is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reinduction chemotherapy with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia. The study is funded by European Commission (HORIZON-MISS-2022-CANCER-01-03, Project ID 101104421)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Disease stage
Required: Stage RELAPSED, REFRACTORY (European leukemia Network (ELN) 2022)
1st or 2nd relapse or refractory according to European leukemia Network (ELN) 2022
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: investigational agent
Participation in another clinical trial with any investigational agents within 14 days or 5 drug half-lives (whatever comes first) prior to randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06713837 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage RELAPSED or REFRACTORY is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages